Efficacy of vemurafenib (V), a selective V600EBRAF inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model.
Brian Higgins
Employment or Leadership Position - Roche/Genentech
Kenneth Daniel Kolinsky
Employment or Leadership Position - Roche/Genentech
Kathleen Schostack
Employment or Leadership Position - Roche/Genentech
Gideon Bollag
Employment or Leadership Position - Plexxikon
Richard J. Lee
Employment or Leadership Position - Roche/Genentech
Fei Su
Employment or Leadership Position - Roche/Genentech
Kathryn Packman
Employment or Leadership Position - Roche/Genentech